Transaction #34299 · Form 4 · 0001829126-26-011387
Veraxa Biotech AG - Post de-SPAC · Purchase · Ordinary Shares
Veraxa Biotech AG - Post de-SPAC · Transacted October 20, 2026 · Filed October 21, 2026
What does this filing report?
An SEC Form 4 filing for Veraxa Biotech AG - Post de-SPAC records a purchase involving Ordinary Shares on October 20, 2026. The reported quantity was 30,000. The filing date is October 21, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0002079109
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 30,000
- Reported price
- 1.09
- Reference value
- 32,700
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 37,932
- Ownership description
- Not reported
- SEC acceptance time
- Oct 21, 2026, 4:10 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Ziegler Christoph Samuel ↗
Director
CIK 0002123272
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Filing footnotes & remarks
No footnotes are available in this record.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.